Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Collagenase for Injection is an enzymatic debriding agent developed and marketed by Grand Life Sciences (Liaoning) Co., Ltd., a subsidiary of Grand Life Sciences Group. Approved in China as a National Class 1 new drug, it is a biologic enzyme designed for wound management and debridement. The drug functions by selectively degrading collagen, a major structural component of the extracellular matrix, within necrotic or devitalized tissue. By breaking down these collagen fibers, the enzyme facilitates the removal of debris from wounds, such as chronic ulcers or burns, without damaging healthy tissue, thereby promoting the natural healing process. While collagenase is frequently used in topical ointment forms, this specific product is formulated as an injection for targeted enzymatic debridement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Collagenase for Injection.